Meroterpenoids with a large conjugated system from Ganoderma lucidum and their inhibitory activities against renal fibrosis

Baoslingzhines Q-X: Structurally previously undescribed trace phenolic meroterpenoids from Ganoderma lucidum and their biological activities toward renal fibrosis and cytotoxicity

Eight previously undescribed phenolic meroterpenoids baoslingzhines Q-X (1-8) including three enantiomeric (±)-baoslingzhines Q-S (1-3) harboring a 2-methylbenzofuran moiety, two trinormeroterpenoids baoslingzhines T and U (4 and 5) containing a 5-methylbenzyl motif as a connection point with another ring, an alkaloid baoslingzhine V (6) possessing 3-methylquinoline, were purified from Ganoderma lucidum. Their planar structures and the absolute configurations were elucidated based on spectroscopic methods and experimental electronic circular dichroism calculations. Compound 6 was capable of diminishing the expression of fibronectin and α-SMA, while compound 8 might dose-dependently attenuate fibronectin and collagen I expression. Besides, inhibition of cell viability of compounds 4-6 toward five human cancer cell lines were observed.

Insights into Ganoderma fungi meroterpenoids opening a new era of racemic natural products in mushrooms

Ganoderma meroterpenoids (GMs) containing 688 structures to date were discovered to have multiple remarkable biological activities. 65.6% of meroterpenoids featuring stereogenic centers from Ganoderma species are racemates. Further, GMs from different Ganoderma species seem to have their own characteristics. In this review, a comprehensive summarization of GMs since 2000 is presented, including GM structures, structure corrections, biological activities, physicochemical properties, total synthesis, and proposed biosynthetic pathways. Additionally, we especially discuss the racemic nature, species-related structural distribution, and structure-activity relationship of GMs, which will provide a likely in-house database and shed light on future studies on GMs.

Ganoderma lucidum-Derived Meroterpenoids Show Anti-Inflammatory Activity In Vitro

Ganoderma lucidum, known as the "herb of spiritual potency", is used for the treatment and prevention of various diseases, but the responsible constituents for its therapeutic effects are largely unknown. For the purpose of obtaining insight into the chemical and biological profiling of meroterpenoids in G. lucidum, various chromatographic approaches were utilized for the title fungus. As a result, six undescribed meroterpenoids, chizhienes A-F (1-6), containing two pairs of enantiomers (4 and 5), were isolated. Their structures were identified using spectroscopic and computational methods. In addition, the anti-inflammatory activities of all the isolates were evaluated by Western blot analysis in LPS-induced macrophage cells (RAW264.7), showing that 1 and 3 could dose dependently inhibit iNOS but not COX-2 expression. Further, 1 and 3 were found to inhibit nitric oxide (NO) production using the Greiss reagent test. The current study will aid in enriching the structural and biological diversity of Ganoderma-derived meroterpenoids.

Isolation and characterization of dihydropyran-ring containing meroterpenoids from Ganoderma lucidum and their inhibitory activity against renal fibrosis-related protein expression

The Ganoderma lucidum mushroom, which has been used as a traditional medicine in China for more than 2000 years, is a source of many interesting natural product. In this study, the five undescribed minor meroterpenoids baoslingzhines F-J (1-5), containing a dihydropyran moiety, were isolated as racemic mixtures from the fruiting bodies of G. lucidum. These substances were structurally and stereochemically characterized by using spectroscopic and computational methods. Chiral HPLC was employed to separate the (+)- and (-)-antipodes. A survey of the activities against kidney fibrosis showed that both enantiomers of baoslingzhines F-J inhibit expression of renal fibrosis-related proteins, including fibronectin, collagen I and ɑ-SMA in TGF-β1-induced rat kidney proximal tubular cells.

A proteoglycan isolated from Ganoderma lucidum attenuates diabetic kidney disease by inhibiting oxidative stress-induced renal fibrosis both in vitro and in vivo

ETHNOPHARMACOLOGICAL RELEVANCE

Ganoderma lucidum (G. lucidum) was regarded as "miraculous herb" by the Chinese and recorded detailly in the "Shen Nong Ben Cao Jing" as a tonic to improve health and prolong life. A proteoglycan (namely, FYGL) was extracted from Ganoderma lucidum, which was a water-soluble hyperbranched proteoglycan, and was found to be able to protect pancreatic tissue against oxidative stress damage.

AIM OF THE STUDY

Diabetic kidney disease (DKD) is a complication of diabetes, but the effective treatment is still lack. Chronic hyperglycemia in diabetic patients induce the accumulation of ROS, which injure the renal tissue and lead to the renal dysfunction. In this work, the efficacy and target mechanics of FYGL on diabetic renal function were investigated.

MATERIALS AND METHODS

In the present study, the mechanism of the reno-protection of FYGL was analyzed on diabetic db/db mice and rat glomerular mesangial cells (HBZY-1) induced by high glucose (HG) with palmitate (PA) (HG/PA). In vitro, the levels of reactive oxygen species (ROS), malondialdehyde (MDA) and superoxide dismutase (SOD) were evaluated by commercial kits. the expressions of NOX1 and NOX4, phosphorylation of MAPK and NF-κB, and pro-fibrotic proteins were measured by Western blot. In vivo, diabetic db/db mice were gavaged with FYGL for 8 weeks, body weight and fasting blood glucose (FBG) were tested weekly. On 8th week, the serum, urine and renal tissue were collected for glucose tolerance test (OGTT), redox indicator (SOD, CAT, GSH and MDA), lipid metabolism (TC, TG, LDL and HDL), blood urea nitrogen (BUN), serum creatinine (Scr), uric acid (UA), 8-oxo-deoxyguanosine (8-OHdG), and the changes of histopathology and expression of collagen IV and AGEs.

RESULTS

The results in vitro showed that FYGL significantly inhibited the HG/PA-induced HBZY-1 cells proliferation, ROS generation, MDA production, promoted SOD activity, and suppressed NOX1, NOX4, MAPK, NF-κB, and pro-fibrotic proteins expression. In addition, FYGL markedly alleviated blood glucose, antioxidant activity and lipid metabolism, improved renal functions, and relieved renal histopathological abnormalities, especially renal fibrosis.

CONCLUSIONS

The antioxidant activity of FYGL can reduce ROS caused by diabetes and protect renal from oxidative stress-induced dysfunction, thereby improving renal function. This study shows that FYGL has the potential to treat diabetic kidney disease.

Diverse meroterpenoids with α-glucosidase inhibitory activity from Ganoderma cochlear

Three new meroterpenoids, cochlearins J-L (1-3) and three known meroterpenoids (4-6) were isolated from the fruiting bodies of Ganoderma cochlear. NMR (¹H and ¹³C NMR, ¹H - ¹H COSY, HSQC, HMBC and ROESY), and HRESIMS were employed for the structure elucidation of new compounds. The stereostructures of 1-3 were confirmed by calculated ECD and optical rotation methods. Furthermore, compounds (+)-1, (-)-1, (+)-2, (-)-2, (+)-3, (-)-3, and 4-6 were evaluated for their α-glucosidase inhibitory activity. The results showed that compounds (+)-1, (-)-1 and (+)-2 exhibited stronger inhibition against α-glucosidase with IC₅₀ values of 24.18 ± 1.98, 26.49 ± 3.20 and 29.68 ± 2.73 μM, respectively, compared to the positive control ursolic acid (49.65 ± 2.21 μM). The molecular docking experiments reveal that (+)-2 and (-)-2 had different binding mode with α-glucosidase, leading to their different inhibition.